Meetings of the JRC. During the Research Term, the JRC will meet in accordance with a schedule established by written agreement of the Parties, but no less frequently than [***], with the location for such meetings alternating between locations designated by RayzeBio and locations designated by PeptiDream. Alternatively, the JRC may meet by means of teleconference, videoconference or other similar communications equipment. PeptiDream will not unreasonably withhold its agreement to more frequent meetings if requested by RayzeBio. In addition, either Party may call an ad hoc meeting of the JRC on [***] notice. Following the Research Term, during the conduct of any activities that are co-funded by the Parties pursuant to Section 7.7, the JRC will meet in accordance with a schedule that the JRC determines. From time-to-time, either Party may invite additional employees of such Party and, with the prior written consent of the other Party, other representatives or consultants, to attend JRC meetings, so long as such representatives or consultants agree in writing to obligations of non-use and confidentiality at least as stringent as those set forth in Article 6 and enter into such agreements necessary for such representative or consultant to be a member of such Party’s Inventor Group for purposes of this Agreement. Each Party will bear its own expenses related to the attendance at the meetings of the JRC by its representatives. At the conclusion of each meeting, the JRC will decide which Party shall prepare and circulate for review and approval of the Parties minutes of such meeting within [***] after the meeting. The Parties shall agree on the minutes of each meeting promptly, but in no event later than [***] after such meeting.
Meetings of the JRC. During the Research Collaboration Term, the JRC shall meet at least once each calendar month either by telephone conference or in a face-to-face meeting, unless otherwise agreed between the Parties. Attendance by at least four (4) JRC members, two (2) from each of BI and Zealand Pharma, at a JRC meeting shall be necessary for the meeting to take place. Either Party may (i) invite its internal alliance manager as non-voting member to the meetings, without prior approval of the other Party, and (ii) invite experts or qualified persons to attend the meetings of the JRC, who will act as Zealand Pharma and/or BI’s advisors, respectively, with the prior approval of the other Party (which approval, shall not be unreasonably delayed or denied), provided that such experts and other persons invited shall be subject to confidentiality and non-use obligations no less stringent than the terms of Article 13. Each Party shall be responsible for all travel and other related costs and expenses for its members and other representatives to attend the meetings of the JRC.
Meetings of the JRC. The JRC shall meet at least once every calendar quarter, unless the JRC co-chairpersons otherwise agree. All JRC meetings may be conducted by telephone, video-conference or in person as determined by the JRC co-chairpersons; provided, however, that the JRC shall meet in person at least once each calendar year, unless the Parties mutually agree to meet by alternative means. Unless otherwise agreed by the Parties, all in-person meetings for JRC shall be held on an alternating basis between Regeneron’s facilities and Sanofi’s facilities. Further, each co-chairperson shall be entitled to call meetings in addition to the regularly scheduled quarterly meetings. The co-chairpersons, with the assistance of the Alliance Managers, shall coordinate activities to prepare and circulate an agenda in advance of each meeting and prepare and issue draft minutes of each meeting within fourteen (14) days thereafter and final minutes within thirty (30) days thereafter, such final minutes to include the updated Target List. With the consent of the Parties (not to be unreasonably withheld or delayed), a reasonable number of other representatives of a Party may attend any JRC meeting as non-voting observers (provided that such additional representatives are under obligations of confidentiality and non-use applicable to the Confidential Information of the other Party that are at least as stringent as those set forth in Article 9 below). Each Party shall be responsible for all of its own personnel and travel costs and expenses relating to participation in JRC meetings.
Meetings of the JRC. During the Research Term, the JRC shall meet by audio or video teleconference twice a year, and once each Calendar Year in person (which in-person meeting shall be held on an alternating basis in the cities of Manchester, England and in San Francisco, California, U.S., or at an agreed to location at a reasonable mid-point location). The research teams will also have periodic research update calls as described in the Research Plan. With the consent of the representatives of each Party serving on the JRC, other representatives of each Party may attend meetings of the JRC as nonvoting observers (provided such representatives: (i) have contractual confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement; and (ii) are under intellectual property assignment obligations to such Party). Meetings of the JRC will be effective only if at least one (1) representative of each Party is present or participating. Each Party shall be responsible for all of its own expenses of participating in JRC meetings. The Parties shall use Reasonable Efforts to schedule meetings of the JRC at least [***] in advance. Upon the conclusion of the Research Term, the JRC will be discontinue [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Meetings of the JRC. The JRC:
Meetings of the JRC. During the Research Collaboration, the JRC shall meet on a quarterly basis either by telephone conference or in a face-to-face meeting, unless otherwise agreed between the Parties. Attendance by at least four (4) JRC members. two (2) from each of BI and Zealand Pharma, at a JRC meeting shall be necessary for the meeting to take place. Either Party may invite experts or qualified persons to attend the meetings of the JRC, who will act as Zealand Pharma and/or BI’s advisors, respectively, with the prior approval of the other Party (which approval shall not be unreasonably delayed or denied), provided that such experts and other persons invited shall be subject to confidentiality and non-use obligations no less stringent than the terms of Article 13. Each Party shall be responsible for all travel and other related costs and expenses for its members and other representatives to attend the meetings of the JRC.
Meetings of the JRC. The JRC shall meet at least once each three (3) month period during the Research Program Term, at such times and places as agreed to by LIGAND and TAP, alternating between San Diego and Lake Forest, or such other locations as the parties shall agree. LIGAND shall be responsible for hosting the first meeting of the JRC. The JRC shall continue to meet after the expiration of the Research Program so long as TAP, its Affiliates or sublicensees are developing Research Compounds that have not commenced Full Development. Meetings of the JRC may be attended by such other directors, officers, employees, consultants and other agents of LIGAND and TAP as the parties from time to time *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. reasonably agree. The party hosting a JRC meeting shall submit an agenda to the other party at least thirty (30) days prior to the JRC meeting the party is hosting. Such an agenda shall be freely amendable by the parties up to five (5) days prior to the meeting. The party hosting each meeting of the JRC promptly shall prepare, and deliver to the other party within fifteen (15) business days after the date of such meeting, minutes of such meeting setting forth all decisions of the JRC relating to the Research Program in form and content reasonably acceptable to the other party. Minutes shall be deemed approved unless any member of the JRC objects to the accuracy of such minutes in writing to the other party within *** after receipt. If a party objects to the minutes and the objection is not resolved, the objection will be deemed a dispute and resolved pursuant to Article 20 hereof. In addition to the quarterly in-person meetings described herein, the JRC may schedule additional in-person and telephonic meetings, as necessary, in which case the party desiring to hold the additional meeting shall be responsible for preparing the agenda and minutes of such meeting as described herein.
Meetings of the JRC. The JRC shall meet at least once each quarter during the Research Term with the location alternating between Princeton, New Jersey and San Diego, California or such other locations as the Parties shall agree. Meetings of the JRC shall be in person, but may be held by telephone or video conference if all members of the JRC so agree. The JRC members will communicate regularly by telephone, facsimile and video conference. Meetings and telephone and video conferences of the JRC may be attended by such other directors, officers, employees, consultants and other agents of Ligand and BMS as the Parties from time to time reasonably agree. Meetings of the JRC shall be effective only if at least one representative of each Party is present or participating. Each Party shall be responsible for all of its own expenses of participating in the JRC meetings.
Meetings of the JRC. The JRC shall hold an initial joint meeting within forty-five (45) days of the Effective Date or as otherwise agreed by the Parties. Thereafter, the JRC shall meet at least once every calendar quarter, unless the JRC co-chairpersons otherwise agree. All JRC meetings may be conducted by telephone, video-conference or in person as determined by the JRC co-chairpersons; provided, however, that the JRC shall meet in person at least once each calendar year, unless the Parties mutually agree to meet by alternative means. Unless otherwise agreed by the Parties, all in-person meetings for JRC shall be held on an alternating basis between Regeneron’s facilities and Sanofi’s facilities. Further, each co-chairperson shall be entitled to call meetings in addition to the regularly scheduled quarterly meetings. The co-chairpersons, with the assistance of the Alliance Managers, shall coordinate activities to prepare and circulate an agenda in advance of each meeting and prepare and issue draft minutes of each meeting within fourteen (14) days thereafter and final minutes within thirty (30) days thereafter, such final minutes to include the updated Target List. With the consent of the Parties (not to be unreasonably withheld or delayed), a reasonable number of other representatives of a Party may attend any JRC meeting as non-voting observers (provided that such additional representatives are under obligations of confidentiality and non-use applicable to the Confidential Information of the other Party that are at least as stringent as those set forth in Article 9 below). Each Party shall be responsible for all of its own personnel and travel costs and expenses relating to participation in JRC meetings.
Meetings of the JRC. The JRC shall meet at least once each quarter during the Term of the Research Program, at such times and places as agreed to by Ligand and Xxxxxx-Xxxxxxx, alternating between San Diego, California and Ann Arbor, Michigan, or such other locations as the Parties shall agree. The JRC and any of its members may meet or attend meetings by telephone or video conference. The JRC will communicate regularly by telephone, facsimile and video conference. Meetings and telephone and video conferences of the JRC may be attended by such other directors, officers, employees, consultants and other agents of Ligand and Xxxxxx-Xxxxxxx as the Parties from time to time reasonably agree.
